Abstract:Abstract Cancer biomarkers have transformed current practices in the oncology clinic. Continued discovery and validation are crucial for improving early diagnosis, risk stratification, and monitoring patient response to treatment. Profiling of the tumour genome and transcriptome are now established tools for the discovery of novel biomarkers, but alterations in proteome expression are more likely to reflect changes in tumour pathophysiology. In the past, clinical diagnostics have strongly relied on antibody-based detection strategies, but these methods carry certain limitations. Mass spectrometry (MS) is a powerful method that enables increasingly comprehensive insights into changes of the proteome to advance personalized medicine. In this review, recent improvements in MS-based clinical proteomics are highlighted with a focus on oncology. We will provide a detailed overview of clinically relevant samples types, as well as, consideration for sample preparation methods, protein quantitation strategies, MS configurations, and data analysis pipelines currently available to researchers. Critical consideration of each step is necessary to address the pressing clinical questions that advance cancer patient diagnosis and prognosis. While the majority of studies focus on the discovery of clinically-relevant biomarkers, there is a growing demand for rigorous biomarker validation. These studies focus on high-throughput targeted MS assays and multi-centre studies with standardized protocols. Additionally, improvements in MS sensitivity are opening the door to new classes of tumour-specific proteoforms including post-translational modifications and variants originating from genomic aberrations. Overlaying proteomic data to complement genomic and transcriptomic datasets forges the growing field of proteogenomics, which shows great potential to improve our understanding of cancer biology. Overall, these advancements not only solidify MS-based clinical proteomics’ integral position in cancer research, but also accelerate the shift towards becoming a regular component of routine analysis and clinical practice.

Discovery and Validation of Clinical Biomarkers of Cancer: A Review Combining Metabolomics and Proteomics

Metabolomics: A Tool to Envisage Biomarkers in Clinical Interpretation of Cancer

Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery.

Mining the Human Proteome: Biomarker Discovery for Human Cancer and Metastases

The prowess of metabolomics in cancer research: current trends, challenges and future perspectives

Metabolomics for searching validated biomarkers in cancer studies: a decade in review

Recent advances in mass spectrometry based clinical proteomics: applications to cancer research

Metabolomics: a Revolution for Novel Cancer Marker Identification.

Metabolomics analysis for biomarker discovery: advances and challenges

Emerging methods and techniques for cancer biomarker discovery

Recent developments in mass-spectrometry-based targeted proteomics of clinical cancer biomarkers

Recent Advances in Proteomics and Cancer Biomarker Discovery

Biomarkers in Cancer Detection, Diagnosis, and Prognosis

Metabolomics in Cancer Biomarker Research

Metabolomics and cellular altered pathways in cancer biology: A review

Proteomics in prostate cancer biomarker discovery

Trends in biomarker research for cancer detection

Clinical proteomics and mass spectrometry profiling for cancer detection

Current Status and Future Prospects of Clinically Exploiting Cancer-specific Metabolism—Why Is Tumor Metabolism Not More Extensively Translated into Clinical Targets and Biomarkers?

Quantitative Proteomics and Biomarker Discovery in Human Cancer

Contemporary Update on Clinical and Experimental Prostate Cancer Biomarkers: A Multi-Omics-Focused Approach to Detection and Risk Stratification